Thompson A J, Lummis S C R
Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK.
Curr Pharm Des. 2006;12(28):3615-30. doi: 10.2174/138161206778522029.
The 5-HT(3) receptor is a member of the Cys-loop family of ligand-gated ion channels. These receptors are located in both the peripheral and central nervous systems, where functional receptors are constructed from five subunits. These subunits may be the same (homopentameric 5-HT(3A) receptors) or different (heteropentameric receptors, usually comprising of 5-HT(3A) and 5-HT(3B) receptor subunits), with the latter having a number of distinct properties. The 5-HT(3) receptor binding site is comprised of six loops from two adjacent subunits, and critical ligand binding amino acids in these loops have been largely identified. There are a range of selective agonists and antagonists for these receptors and the pharmacophore is reasonably well understood. There are also a wide range of compounds that can modulate receptor activity. Studies have suggested many diverse potential disease targets that might be amenable to alleviation by 5-HT(3) receptor selective compounds but to date only two applications have been fully realised in the clinic: the treatment of emesis and irritable-bowel syndrome.
5-羟色胺(3)受体是半胱氨酸环家族配体门控离子通道的成员。这些受体位于外周和中枢神经系统,功能性受体由五个亚基构成。这些亚基可能相同(同五聚体5-羟色胺(3A)受体)或不同(异五聚体受体,通常由5-羟色胺(3A)和5-羟色胺(3B)受体亚基组成),后者具有许多独特的特性。5-羟色胺(3)受体结合位点由两个相邻亚基的六个环组成,这些环中关键的配体结合氨基酸已基本确定。针对这些受体有一系列选择性激动剂和拮抗剂,其药效基团也得到了较好的理解。还有多种化合物可调节受体活性。研究表明,许多不同的潜在疾病靶点可能适合用5-羟色胺(3)受体选择性化合物缓解,但迄今为止,临床上仅实现了两种应用:治疗呕吐和肠易激综合征。